A PHASE 1 SINGLE AND MULTIPLE DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMIC EFFECTS OF ARO-APOC3 IN ADULT HEALTHY VOLUNTEERS AS WELL AS IN SEVERELY HYPERTRIGLYCERIDEMIC PATIENTS AND PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME.
- Registry ID
- AROAPOC31001
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- ARROWHEAD PHARMACEUTICALS, INC.
- Start date
- 2020-03-04
- Completion date
- 2021-02-11
- Last update
- 2020-01-22
Conditions
- HYPERTRIGLYCERIDEMIA
- FAMILIAL CHYLOMICRONEMIA SYNDROME
Related clinical trials
- A PHASE 2, OPEN-LABEL TRIAL EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF ION775 IN ADULTS WITH HYPERTRIGLYCERIDEMIA
- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 (SOLBINSIRAN) IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SOLARIS-1)
- A PHASE 3 OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF
PLOZASIRAN IN ADULTS WITH HYPERTRIGLYCERIDEMIA (SHASTA-10 STUDY)
- DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF
PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHASTA-3 STUDY)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS WITH SEVERE HYPERTRIGLYCERIDEMIA
(SHTG
- AN OPEN-LABEL EXTENSION STUDY OF OLEZARSEN (ISIS 678354) ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG)
View on source registry